“It takes time to move a technology from bench to bedside. When it comes to DNA testing to determine if breast cancer patients are likely to benefit from tamoxifen, that wait needs to end,” stated NFCR President Franklin C. Salisbury, Jr.
Filed under: Personalized Medicine | Tagged: breast cancer, CYP2D6, Personalized Medicine, Pharmacogenetics | 2 Comments »
